Improved classification of breast cancer peptide and protein profiles by combining two serum workup procedures by Berit Velstra et al.
ORIGINAL PAPER
Improved classification of breast cancer peptide and protein
profiles by combining two serum workup procedures
Berit Velstra • Yuri E. M. van der Burgt •
Bart J. Mertens • Wilma E. Mesker •
Andre´ M. Deelder • Rob A. E. M. Tollenaar
Received: 30 March 2012 / Accepted: 15 June 2012 / Published online: 5 July 2012
 The Author(s) 2012. This article is published with open access at Springerlink.com
Abstract
Purpose Detection of breast cancer at early stage
increases patient’s survival. Mass spectrometry-based
protein analysis of serum samples is a promising approach
to obtain biomarker profiles for early detection. A combi-
nation of commonly applied solid-phase extraction proce-
dures for clean-up may increase the number of detectable
peptides and proteins. In this study, we have evaluated
whether the classification performance of breast cancer
profiles improves by using two serum workup procedures.
Methods Serum samples from 105 breast cancer patients
and 202 healthy volunteers were processed according to a
standardized protocol implemented on a high-end liquid-
handling robot. Peptide and protein enrichments were
carried out using weak-cation exchange (WCX) and
reversed-phase (RP) C18 magnetic beads. Profiles were
acquired on a matrix-assisted laser desorption/ionization
time-of-flight (MALDI-TOF) mass spectrometer. In this
way, two different biomarker profiles were obtained for
each serum sample, yielding a WCX- and RPC18-dataset.
Results The profiles were statistically evaluated with
double cross-validation. Classification results of WCX- and
RPC18-datasets were determined for each set separately
and for the combination of both sets. Sensitivity and
specificity were 82 and 87 % (WCX) and 73 and 93 %
(RPC18) for the individual workup procedures. These
values increased up to 84 and 95 %, respectively, upon
combining the data.
Conclusion It was found that MALDI-TOF peptide and
protein profiles can be used for classification of breast
cancer with high sensitivity and specificity. The classifi-
cation performance even improved when two workup
procedures were applied, since these provide a greater
number of features (proteins).
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LIN Linear discriminant analysis
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RF Random forest combination
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Introduction
With an increasing lifetime risk, currently estimated as one
in eight, breast cancer is a leading cause of cancer-related
morbidity and mortality (Veronesi et al. 2005). Neverthe-
less, the mortality rate has decreased over the last decade
(Jemal et al. 2009). One of the reasons for this decrease
includes early detection through widespread mammogra-
phy screening (Etzioni et al. 2003). To this end, in many
countries, mammography is used as a population-based
screening method in women older than 50 years. Unfor-
tunately, up to 20 % of new breast cancer incidents are not
detected by this X-ray method, and for younger women
with a genetic predisposition, sensitivity is not more than
40 %. Furthermore, specificity of the method is relatively
low since only one out of three lesions is found to be
malignant (Astley 2004; Benson et al. 2004; Roder et al.
2008). As a result, mammography screening may lead to
overdiagnosis (Brennan et al. 2009). From these draw-
backs, it becomes obvious that there is an urgent need for
novel molecular markers that can improve both sensitivity
and specificity for early detection of breast cancer.
A minimally invasive, sensitive, and more specific
alternative to mammography could be the use of protein
biomarkers in a peripheral blood (serum) test. Mass spec-
trometry (MS) has shown to be a powerful technology for
detection, quantification, and identification of proteins in
various body fluids (Aebersold and Mann 2003; Nilsson
et al. 2010). So-called MS-based proteomics has benefitted
greatly from both instrumental innovations and technolog-
ical progress in terms of improved resolution, mass
accuracy, robustness, and dynamic range of the mass spec-
trometer as well as from an interest for application in the
clinic (Galvao et al. 2011; Ludwig and Weinstein 2005;
Palmblad et al. 2009). In a classical profiling study, the aim
is to map as many peptides and/or proteins of an individual’s
serum or urine sample in one single mass spectrum. These
peptide and protein patterns can change as a result of disease
and are thus helpful in both early detection and monitoring
the development of the disease. However, body fluids are
very complex mixtures of biomolecules and therefore
require appropriate sample workup (Callesen et al. 2008). In
addition to the complexity, the peptide and protein profiles
of serum are usually dominated by highly abundant species
(Anderson and Anderson 2002). This limitation on the
dynamic range can be partly overcome by using advanced
separation techniques that yield a defined subset of the
proteome. Moreover, new and improved MS systems have
been developed to meet the challenge of complexity inher-
ent to biological samples. A promising improvement is to
combine various purification methods, thus enhancing the
number of detectable peptides and proteins and thereby
increasing the odds to find potential biomarkers.
A suitable strategy for protein and peptide extraction is
based on the use of functionalized magnetic beads (MBs).
Such solid-phase extraction (SPE) has been widely applied
for profiling studies in combination with matrix-assisted
laser desorption/ionization (MALDI) time-of-flight (TOF)
MS (Alagaratnam et al. 2008; Baumann et al. 2005; de
Noo et al. 2005, 2006b; Dekker et al. 2005; Jimenez et al.
2007; Nadarajah et al. 2012). For each serum sample fresh,
disposable MB-s are used, thus avoiding carry-over that
may occur with other techniques such as liquid chroma-
tography (LC). Moreover, MBs with a different function-
ality allow protein and peptide enrichment based on
different chemical–physical interactions, thereby broaden-
ing the range of components covered. Various research
groups have been evaluating a proteomic profiling
approach (Belluco et al. 2007; de Noo et al. 2006a; Fan
et al. 2010; Pietrowska et al. 2009; van Winden et al. 2009;
Villanueva et al. 2006). Previously, our group has shown
that profiles generated from functionalized magnetic beads
fractionated serum could differentiate individuals with
breast cancer from healthy individuals (de Noo et al.
2006a). In the current study, two different types of MBs,
namely weak-cation exchange (WCX) and reversed-phase
(RP)C18, were used to generate potentially complementary
profiles. The two types of MBs cover a different range of
the serum peptidome and proteome, that is, WCX-MBs
bind hydrophilic proteins that are mass analyzed up to
11 kDa, whereas RPC18-MBs generally bind (smaller)
hydrophobic peptides that are mass analyzed up to 4 kDa.
Aiming for an increased sensitivity and specificity for the
detection of breast cancer, we have integrated the analysis
of WCX and RPC18 profiles. In this study, it will be
shown that the classification performance for breast cancer
improves when data from two complementary workup
procedures are used.
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Materials and methods
An overview of sample collection, sample and profile
processing, and data analysis is depicted in Fig. 1. The
sample workup is performed through both a WCX- and an
RPC18 MB pipeline.
Patient characteristics
Serum samples were obtained from 105 female patients
with breast cancer (diagnosed by routine pathological
analysis) prior to surgery, and from 202 female healthy
volunteers (control group) without breast cancer. The
median age of the breast cancer patients was 62 years
(range, 22–92 years) and of the control group 49 years
(range, 18–80 years). Serum samples were obtained in the
outpatient clinic of the Leiden University Medical Center
(LUMC), The Netherlands, between October 2002 and
December 2008. Informed consent was obtained from all
subjects, and the study was approved by the Medical Eth-
ical Committee of the LUMC. Female healthy volunteers
were accompanying persons.
Serum samples
Samples were collected and processed according to a
standardized protocol: all blood samples were drawn by
antecubital venapuncture while the individuals were seated
and had not been fasting. For patients, sample collection
was performed pre-operative, for healthy individuals at the
outpatient clinic. The samples were drawn in an 8.5-cc
Serum Separator Vacutainer Tube (BD Diagnostics,
Plymouth, UK) and within maximally 4 h centrifuged at
room temperature at 1,000 g for 10 min (de Noo et al.
2005). Until aliquoting, samples were kept in sterile 500-ll
barcode-labeled polypropylene tubes (TrakMate, Matrix
TechCorp.) at -80 C until aliquoting. To this end, sam-
ples were thawed on ice in a standardized way and placed
in barcode labeled racks in an 8-channel Hamilton STAR
pipetting robot (Hamilton, Bonaduz, Switzerland) for
automated aliquoting of 60 ll into daughter tubes. These
aliquots were again stored at -80 C until further sample
processing.
Automated serum workup procedures
Two sequential SPE workup procedures were performed
for each serum sample, using only one 60 ll aliquot.
First, 5 ll of serum was used for peptide and protein
enrichment with a WCX profiling kit from Bruker Dal-
tonics (Bremen, Germany). This kit contained MBs, as well
as binding-, washing- and stabilization-buffers. The man-
ufacturer’s instructions were followed with optimizations
that allowed for automation on a 96-channel Hamilton
STARplus pipetting robot, including additional activa-
tion and washing steps (Hamilton, Bonaduz, Switzerland).
In short, for each sample, a fresh suspension of 10 ll of
paramagnetic monodisperse WCX beads was used in a
96-well PCR microtiter plate (MTP) format. WCX-MB
binding solution (10 ll) and 5 ll serum sample were added
to the beads and carefully mixed using the robot. After
5-min incubation, a magnet was applied for 30 s to allow
for optimal settlement of the MBs at the bottom of each
well. The supernatant was removed, and the MBs were
washed three times with WCX-MB washing buffer.
Finally, the peptides and proteins were eluted from the
beads using 10 ll custom-made ammoniumhydroxide











Statistical analysis of data
1. Linear Mixture Combination
2. Random Forest Combination
3. Logistic Regression Calibration Combination
Data Processing
a. Baseline correction and alignment of profiles
b. Removal of low-quality profiles
c. Peak selection and -quantification
WCX RPC18
Fig. 1 Overview of two sequential processing methods (WCX and
RPC18 magnetic beads) for the generation and evaluation of serum
peptide profiles. a Automated fractionation of samples with both
WCX and RPC18 MBs separately. Storage at -80 C of the MTP’s
until measurement. Automated spotting in quadruplicate on MALDI-
plate for WCX and RPC18 fractionated samples. b Measurements of
MALDI-plates in MALDI-TOF. c Profile processing: I Baseline
correction & alignment of four profiles per sample. II Removal of
spectra without any signal due to spotting failure (max 2.5 %). III
Selection of interesting peaks and extraction of this data with
Xtractor. d Data analysis on mean of remaining profiles. Analysis of
profiles from the WCX and the RPC18 magnetic bead pipeline
separately with LIN and RF. Summarization of the within-bead
profiles using double cross-validation predictions. Combination of the
predictions of both the WCX and RPC18 data by LIN, RF, and LG
analyses
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buffer (NH4OH, pH 10). Thus, obtained eluates were
transferred to a fresh 96-well eluate plate where WCX-MB
stabilization buffer was added (10 ll). Two microliters of
the stabilized eluate were transferred to a fresh 384-well
mixing plate. Fifteen microliters of a-cyano-4-hydroxy-
cinnamic acid (0.3 g/l in ethanol/acetone 2:1) (MALDI-
matrix) was added and mixed carefully by the Hamilton
pipetting robot. This mixture was spotted in quadruplicate
onto a MALDI AnchorChipTM (600 lm, Bruker Daltonics)
target plate using 1 ll for each spot.
Second, 5 ll of serum (from the same aliquot) was used
for peptide enrichment with RPC18-functionalized MBs
(Jimenez et al. 2007; Nicolardi et al. 2010). For this pur-
pose, 10 ll of RPC18 Dynabeads (Invitrogen) was used for
the analysis of 5 ll human serum. The activation, washing
and desorption steps of the RPC18 beads were based on the
manufacturers protocol and optimized to allow imple-
mentation on the 96-channel pipetting robot. For optimal
removal of preservatives during the activation step, the
RPC18 beads were washed three times with 50 ll of water.
For similar reasons, after binding of the peptides to the
RPC18 beads, three washing steps with 50 ll of a 0.1 %
trifluoroacetic acid (TFA) solution were carried out.
Finally, in the peptide desorption step, the remaining
peptides and proteins were eluted with 15 ll 50 % aceto-
nitrile (ACN) solution and transferred into a 96-well plate
and mixed with stabilization buffer. A portion of these
eluates (2 ll) was used for MALDI-spotting. The
96-channel Hamilton pipetting robot was used for mixing
of sample eluates with MALDI-matrix, followed by spot-
ting on a MALDI target plate. To this end, 2 ll of the
stabilized eluate was transferred into a fresh 384-well MTP
and mixed with 10 ll of a-cyano-4-hydroxycinnamic acid
(0.3 g/l in ethanol/acetone 2:1). This mixture was spotted
in quadruplicate onto a MALDI AnchorChipTM (600 lm)
target plate using 1 ll for each of the 384 spots.
MALDI-TOF–MS peptide and protein profiling
After MALDI spotting, the target plates were immediately
placed into a storage chamber (RT, 5 % oxygen, 95 %
nitrogen). For MALDI-TOF measurements, each plate was
transferred to the mass spectrometer using a robotic system
for automated plate loading (Thermo Fisher Scientific Inc.,
USA). This offers the possibility to carry out all MALDI-
TOF measurements within 12 h after spotting using the
96-channel robot. MALDI-TOF mass spectra of the pro-
teins in the WCX eluates were obtained using a positive-
ion linear mode acquisition on an Ultraflex III TOF/TOF
mass spectrometer (Bruker Daltonics, Bremen, Germany)
equipped with a SCOUT ion source and controlled by the
Flexanalysis 3.0 software package (Bruker Daltonics). Ions
generated by the SmartBeamTM 200 Hz solid-state laser,
set at a frequency of 100 Hz, were accelerated to 25 kV
and mass analyzed from 960 to 11,024 Da.
MALDI-TOF mass spectra of peptides in the RPC18
eluates were obtained using the same Ultraflex III TOF/
TOF mass spectrometer operating in positive reflectron
mode in the m/z-range of 600–4,000. Sixty laser shots were
accumulated for each raster spot, and the sum of 1,200
satisfactory shots, in 60 shot steps, was used for each
spectrum (WCX and RPC18). Each profile was obtained
after summation of 20 mass spectra. The spectra were
externally calibrated using a commercially available pep-
tide mix (Bruker Daltonics). FlexAnalysis Software 3.0
was used for visualization and initial data processing.
Profile processing
In total, 307 serum samples were processed with two types of
MBs and MALDI-TOF profiles were obtained in quadru-
plicate, yielding 1228 WCX- and 1228 RPC18-profiles. For
optimal data analysis, all WCX- and RPC18-profiles
required baseline correction followed by alignment (see
Fig. 1). First, a baseline subtraction of all profiles was per-
formed using the baseline subtraction tool of FlexAnalysis
3.0. Second, to perform the alignment of all 384 RPC18
profiles from one MALDI target plate, at least three peptides
at different m/z-values were essential for internal calibration.
In order to compensate for the possible absence of one or two
peptides in a spectrum, the following five peptides were
selected based on a manual inspection of a few spectra,
namely at m/z 1,465.8, m/z 1,778.1, m/z 1,865.2, m/z 2,602.5,
and at m/z 2,931.5, with a tolerance window of 100 ppm for
the m/z 1,465.8 peak increasing up to 300 ppm for the highest
m/z-value (FlexAnalysis 3.0). Similarly, for WCX profiles,
the following 7 peaks were visually selected: m/z 1,866.1,
3,158.0, 4,643.6, 5,903.7, 6,631.1, 7,765.5, and 9,290.9. In a
next step, all low-quality profiles (as a result of failed sample
workup or bad MALDI spotting) were excluded from sta-
tistical analysis [n = 33 for WCX profiles (2.7 %) and
n = 8 for RPC18-profiles (0.7 %)]. The remaining MALDI-
TOF profiles were exported as DAT (.dat) files, all contain-
ing m/z-values with corresponding intensities. Finally, pro-
tein and/or peptide signals in both WCX- and RPC18-
profiles were quantified as follows. First, based on visual
inspection of the profiles, 48 signals in WCX and 42 signals
in RPC18 were selected for further analysis. To this end, a so-
called reference file was compiled for both types of profiles
including a certain m/z-window for each signal or peak. In
the WCX profiles, this m/z-window reflected the peak width
and varied from 5 to 30 Da. In the RPC18-profiles, all peaks
were isotopically resolved and of similar shape and width,
thus suitable for a fixed window of 0.49 Da. Two examples
of selected peaks are shown in Fig. 2. Then, the in-house
developed Xtractor tool was used to determine the intensity
1986 J Cancer Res Clin Oncol (2012) 138:1983–1992
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of each user-defined peak (Selman et al. 2010). This open
source tool generates uniform data (peak) arrays regardless
of spectral content (ms-utils.org/Xtractor). In the case of
RPC18 profiles, peak intensities were determined for each
individual isotope of the 42 selected peptide clusters. This
detailed information was used for quality control (QC) based
on isotopic distribution as reported previously (Nicolardi
et al. 2010). For the purpose of this study, the peak intensities
of individual isotopes were summed for each isotopic cluster,
resulting in a single intensity value for each peptide. The
mean of the remaining profiles of the quadruplicate spots for
both the WCX and the RPC18 purified samples was used for
statistical analysis, as reported previously (Mertens et al.
2011). These processed profiles will be further referred to as
the WCX dataset and RPC18 dataset, respectively.
Data processing and statistics
The WCX- and RPC18-datasets were statistically evalu-
ated as overviewed in Fig. 1. First, a double cross-valida-
tory implementation of linear discriminant analysis (LIN)
for the calibration of a diagnostic rule based on a single
(mean) spectrum per patient and per magnetic bead was
performed, as described previously (de Noo et al. 2006b;
Mertens et al. 2006). Next, the predictive performances of
both sets (WCX and RPC18) were combined to test whe-
ther this improved the performance. For this analysis, the
original sets of predictors X1 an X2 were replaced by the
sets of double cross-validated predicted probabilities
p1 = (p1
1, …, pn1)T and p2 = (p12, …, pn2)T. The predictions
p1 and p2 were combined in a linear mixture combination
(MIX). A confirmatory secondary analysis to check the
results of the MIX was carried out using the random forest
(RF) classification approach as well as using a logistic
regression calibration (LG) combination. For each analysis
brier score, deviance, sensitivity, specificity, total recog-
nition rate, and area under the curve (AUC) were calcu-
lated. This procedure and definitions have been described
in detail by Mertens et al. (2011).
Results
Classification performance
The classification results of WCX and RPC18 datasets
were determined for each set separately and for the com-
bination of both sets. In Table 1, the double cross-valida-
tory classification performance measures are shown for
WCX and RPC18 datasets independently as well as for the
combination of the datasets. As becomes clear from
Table 1, all classification performance metrics improved
when the combination was compared to the single WCX or
RPC18 results. For WCX and RPC18, the total recognition
rate using linear discriminant analysis (LIN) was 0.85 and
0.86, respectively, and improved for the integrated datasets
in the linear mixture combination (MIX) to 0.91. Likewise,
the Brier score improved for the combination WCX and
RPC18 [0.084 (MIX) compared to 0.11 WCX (LIN) and
0.11 RPC18 (LIN)]. Furthermore, the deviance improved
markedly for the combination. This indicates that not only
the total recognition rate improves but also the accuracy of
calculation of the class probabilities, which is important
from a patient perspective. The improved predictions in the
combination also become apparent from two scatter plots
of both the WCX- and RPC18- datasets, one including all
cases and one all controls (Fig. 3). In these plots, on the
left, the incorrectly assigned cases are depicted in the first
(upper-left), third (lower-left), and fourth (lower-right)
quadrant, with discrepancies between the WCX- and
RPC18-based assignments in the first and fourth quadrant.
For the cases, there are 29 observations in the first and
fourth quadrants of which 21 are classified correctly in the
integrated dataset. Subsequently, for the control group, 24
Fig. 2 Two examples of the selected peaks for WCX fractionated
sample profiles and RPC18 fractionated sample profiles, respectively.
On the x-axis, m/z-values are shown, on the y-axis, intensities. Note
that WCX-MBs select proteins that are mass analyzed up to 11 kDa,
whereas RPC18-MBs generally select smaller peptides up to 4 kDa
J Cancer Res Clin Oncol (2012) 138:1983–1992 1987
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out of 28 observations in these quadrants are recovered by
the combination. In the second and third quadrant, there are
no discrepancies between both methods for the cases and
control groups. In total, there are 234 of such observations,
of which 67 in the cases group and 167 in the control
group. Only for a few observations, WCX- as well as
RPC18-profiles lead to miss-classification (third quadrant),
and merging these data does not result in an improved
classification. In the case group, these are nine observations
and in the control group seven. The classification
improvement is due to 45 (21 ? 24) out of 57 observations
in the first and fourth quadrant shifting to the correct
assignment as well as improvement in precision of the
calibrated posterior class probabilities. In short, by using
two complementary SPE methods, more patients are cor-
rectly classified and with higher precision.
Peak performance
In order to determine the most discriminating peaks, a
weighted coefficient of variability of peak expression was
calculated for both the 48 peaks selected from WCX pro-
files as well as the 42 peaks selected from the corresponding
RPC18 spectra (For further details, see supplementary file).
For WCX, a cut-off point of ?2/- 2 of the weighted dis-
criminant coefficient scale was taken and ten peaks
remained. Similarly, for RPC18, a selected cut-off point of
?3.75/- 3.75 resulted in sixteen discriminating peaks. For
WCX and RPC18 separately thus remaining peaks were
used to recalibrate the within-bead-based discrimination
rule and check whether discriminative performance was
maintained after selection. An Independent Student’s t test
on the case–control data of the ten (WCX) and sixteen
(RPC18) peaks was performed for further selection of the
most discriminating peaks (p values). This test resulted in
Table 1 Double cross-validatory classification performance mea-
sures from the left to the right for WCX and RPC18 profiles inde-









Sensitivity 0.82 0.73 0.84
Specificity 0.87 0.93 0.95
Brier 0.11 0.11 0.084





AUC 0.91 0.89 0.94
Fig. 3 Separate scatter plots for cases and controls versus the double
cross-validatory posterior class probabilities calculated from the
WCX spectral data (on the y-axis) and from the RPC18 spectral data
(x-axis). For cases, symbols are plotted green when correctly
classified by the LIN and green with a red circle when otherwise.
In the second quadrant, cases are displayed that are correctly
classified by both methods. In the third quadrant, cases that are
misclassified by both methods are shown. The first and fourth
quadrant show discrepancies between the WCX- and RPC18-based
assignments. The green dots represent the patients that are recovered
by the combination. In both of these quadrants, it is clear that there
are more correctly assigned cases than incorrectly assigned. For
controls, symbols are plotted blue when correctly classified and
plotted blue with a red circle when otherwise
1988 J Cancer Res Clin Oncol (2012) 138:1983–1992
123
six significant peaks for discriminating cases from controls
for WCX and sixteen for RPC18, respectively. These
results, including standard deviations and confidence
intervals, are summarized in Table 2. Note that all signifi-
cant peaks in the RPC18 profiles had a positive t value,
which indicates that lower expression of these peaks results
in a lower chance of being a case.
Discussion
Early detection of breast cancer remains a major challenge in
medicine. Clinical proteomics has emerged as powerful
strategy to develop novel tools for this early diagnosis. In this
study, peptide and protein profiles of human serum were
obtained aiming at detecting specific patterns present in
patients with breast cancer. It was found that peptide and
protein profiles can be used to classify breast cancer from
healthy control individuals at a sensitivity of 84 % and a
specificity of 95 % by using datasets obtained from two
complementary SPE methods. Earlier, differentiating pro-
tein profiles was reported by our group using C8-function-
alized MBs (de Noo et al. 2006a). Although the C8-results
were very similar, the current results cannot be qualified as a
validation series since the applied MBs were different.
Breast cancer serum profiles have been classified with sim-
ilar success using two other strategies for sample workup,
namely with surface-enhance laser desorption/ionization
(SELDI) chips and by serum fractionation using a low-
molecular-weight cut-off filter (Pietrowska et al. 2009). The
Table 2 Independent samples t Test for 10 most discriminating WCX peaks and 16 RPC18 peaks together with the corresponding m/z-value in
Dalton (Da) as determined from previous identification studies (Tiss et al. 2010)
Mass t value SD p value CI Identification Swissprot
WCX
Peak 4 2,024 -0.8,594 1.0549 0.3908 -0.3588 0.1407 –
Peak 8 2,770 -6.1616 0.8310 0.000* -0.8127 -0.4193 –
Peak 15 3,328 -2.7924 0.9126 0.0056* -0.5226 -0.0905 –
Peak 17 3,956 -1.2240 0.9412 0.2219 -0.3614 0.0842 –
Peak 23 4,480 0.1183 0.8964 0.9059 -0.1995 0.2250 –
Peak 25 4,963 -3.1870 0.8178 0.0016* -0.5072 -0.1200 –
Peak 29 5,248 -3.9337 0.7699 0.0001* -0.5467 -0.1821 –
Peak 33 5,920 -6.7727 0.9371 0.000* -0.9854 -0.5417 –
Peak 46 8,939 0.3956 1.0182 0.6927 -0.1926 0.2895 –
Peak 48 10,270 -4.3848 0.9209 0.000* -0.7038 -0.2678 –
RPC18
Peak 3 1,206 4.7685 10.6372 \0.001* 3.5843 8.6208 FGA (5–16) P02671
Peak 4 1,211 5.6199 10.9054 \0.001* 4.7917 9.9551 –
Peak 13 1,449 5.8529 10.7419 \0.001* 5.0209 10.1070 FGA (2–16) H2O P02671
Peak 14 1,465 4.6336 10.5497 \0.001* 3.3835 8.3786 FGA (2–16) P02671
Peak 23 1,691 5.7363 10.7685 \0.001* 4.8824 9.9811 –
Peak 25 1,778 6.0120 10.8404 \0.001* 5.2745 10.4073 –
Peak 26 1,865 6.2572 11.1124 \0.001* 5.7346 10.9961 Complement C3f (1–16) P01024
Peak 29 2,021 5.1194 11.0438 \0.001* 4.1875 9.4165 –
Peak 30 2,271 5.8021 10.8978 \0.001* 5.0273 10.1872 ITIH4 Q14624
Peak 33 2,602 5.6578 11.0884 \0.001 * 4.9227 10.1728 –
Peak 36 2,768 4.9575 10.8455 \0.001* 3.9010 9.0362 FGA (576–600) P02671
Peak 37 2,931 5.0365 11.1779 \0.001* 4.1269 9.4195 FGA 576–601) P02671
Peak 39 3,156 5.5067 11.0767 \0.001* 4.7160 9.9607 ITIH4 (617–644) Q14624
Peak 40 3,190 4.9785 10.9766 \0.001* 3.9760 9.1732 –
Peak 41 3,261 4.8202 11.0915 \0.001* 3.8064 9.0580 FGA (576–604) P02671
Peak 42 3,954 5.6858 11.0251 \0.001* 4.9316 10.1518 ITIH4 (645–681) Q14624
All t values, standard deviations (SD), p values, confidence intervals (CI), and identifications with corresponding Swissprot codes are listed in
rows
A p value \ 0.05 was considered significant and marked in this table with *
FGA fibrinogen alpha, ITIH4 inter-alpha-trypsin inhibitor heavy chain H4
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importance of controlling the collection of clinical samples,
storage conditions, experimental design, spectrometric
instruments, and bioinformatics analyses has been stressed in
various biomarker discovery studies using MS-based pro-
teomics profiling technology (de Noo et al. 2005; Diamandis
2004; Villanueva et al. 2004). In the current study, we spe-
cifically designed our workflow to minimize biases with
respect to patient-control handling differences, or variations
in sample collection, processing, and storage. A generally
recognized pitfall in MS-based profiling studies concerns the
large dynamic range in protein concentrations in any body
fluid. No single method or instrument can measure all pro-
teins in a biological sample, which are typically character-
ized by a wide range of protein abundances (and often
proteins of interest are expressed at a low abundance).
Sample fractionation can overcome these issues and reduces
the impact of under-sampling and improves reproducibility
between analyses (Nilsson et al. 2010). To this end, com-
bining two SPE approaches could result in higher sensitivity
for interesting proteins and peptides.
Like in other research fields, at the basis of any well-
designed clinical trial lies method development to find the
most robust, in this case best reproducible platform for
proteomic profiling. In this paper, an improvement at the
bioinformatics level is presented by merging data from two
MB-strategies. It should be emphasized that the combination
of protein profiles, that is, mass spectra, from multiple plat-
forms is not straightforward. The use of support vector
machines has resulted in powerful classifications with
promising potential for biomarker discovery (Gianazza et al.
2010; Chinello et al. 2010). However, such an approach is not
feasible (yet) for combination of MS-based profiles obtained
from different platforms. In this work, both low-resolution
TOF and high-resolution TOF profiles were used for classi-
fication of serum samples and these profiles cannot be simply
summed to one single spectrum. Moreover, the combination
of data is difficult because this may easily be affected by
systematic differences in scaling that causes problems for
most standard shrinkage methods, such as dimension
reduction-based approaches. In the paper from Mertens et al.
(2011), this is further illustrated and clarified. However, data
can be merged based on the predictions provided proper
cross-validation is applied as shown in this paper. It was
previously shown that an approach of linear combination
provides a valid model for comparing prediction perfor-
mance and that furthermore such relatively simple models
are preferred with respect to the interpretation of the data
(Bovelstad et al. 2007; Hand 2006). Therefore, in this work,
the predictions of multiple profiles obtained from the same
patient (or control) sample were linearly combined, and it
was found that the classification performances improved. An
explanation for this improvement could be that the integrated
datasets consider more discriminative proteins and/or
peptides. However, it may also be that both methods char-
acterize different cleaving products (degradation) from the
same protein. In that case, the analysis could be interpreted as
if two independent measurements had been performed, and
thus, the results improve in a similar way as when taking the
mean of two experiments. It is possible that combining the
data here presented with other distinct ‘omics’ data will
result in an even better discriminating performance. It should
be noted that the strategy used in this work for integrating
multiple datasets forms a general template for the problem of
predictive calibration and that further combinations are
currently evaluated.
Generally, in a first step of a peptide or protein profiling
study, the diagnostic power of candidate markers is deter-
mined. As a second step, identification studies and further
investigations into their biological role in disease mecha-
nisms are performed. Note that the identification of peptide
or protein signals in a profile is not straightforward. Such
efforts require specific separation- or enrichment-strategies
as well as a high quality of tandem MS (MS/MS) data for
identification of endogenous species, that is, large coverage
of fragment ions (Nicolardi et al. 2012). Most reports on
serum peptide identifications in profiles are based on SELDI
enrichment chips (i.e., Immobilized Metal Affinity Capture
(IMAC) or on RPC18 SPE procedures (Nicolardi et al. 2011;
Tiss et al. 2010; Villanueva et al. 2006). Considering the
sixteen most discriminating RPC18 peaks found in this study
(Table 2), these peaks can be matched as fragments of FGA-
chain (m/z-values at 1,206, 1,449, 1,465, 2,768, 2,931, and
3,261—P02671), fragments of complement C3 (m/z-value at
1,865 Da—P01024) and Inter-alpha-trypsin inhibitor
(ITIH4) (m/z-values at 2,271, 3,156, and 3,954—Q14624)
(Tiss et al. 2010). Note that all significant peaks for RPC18
were found with positive t values. This is probably due to the
fact that peptides under the selected peaks are part of the
same protein, as previously described by Villanueva as en-
doproteolytic cleaving products (Villanueva et al. 2006). It is
recognized that inconsistencies in intensity and direction of
discrimination and lack of confirmation in other studies
make that these proteins as single marker alone have not yet
been proven to be reliable for breast cancer identification
(Fan et al. 2010). Although a single peptide or protein can be
a biomarker molecule in itself, we hypothesize that a full
profile is more powerful in terms of specificity. This
hypothesis is supported by the fact that in this study all
peptides or proteins were found at different discriminating
powers as when a larger group of peaks was taken.
Conclusions
In this study, it was shown that breast cancer MALDI-TOF
peptide and protein profiles can be used to classify breast
1990 J Cancer Res Clin Oncol (2012) 138:1983–1992
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cancer patients from healthy volunteers with good sensi-
tivity and specificity based on the SPE-fractionation using
two different magnetic beads. The full automation of the
workup procedures ensured a standardized and robust
peptide and protein isolation procedure. Combining the
data resulting from two complementary workup procedures
improved the classification results. The discriminating
power or deviance of analyses of both datasets (WCX and
RPC18) was very promising compared to conventional
mammography results. The integration of datasets from
two complementary workup procedures even further
improved the classification results. Currently, larger patient
sets are analyzed for validation and MS/MS will be used to
identify the discriminating proteins and peptides for its use
in breast cancer screening programs.
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